Saltar al contenido
Merck

SML0124

Sigma-Aldrich

Rasagiline mesylate

≥98% (HPLC)

Sinónimos:

(1R)-2,3-Dihydro-N-2-propynl-1H-inden-1-amine methanesulfonate, N-Propargyl-1(R)-aminoindan methanesulfonate, TVP-1012

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C12H13N · CH4O3S
Número de CAS:
Peso molecular:
267.34
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +15 to +28°, c = 0.6 mg/mL in H2O

storage condition

desiccated

color

white to tan

solubility

H2O: ≥20 mg/mL

storage temp.

2-8°C

SMILES string

CS(O)(=O)=O.C#CCN[C@@H]1CCc2ccccc12

InChI

1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1

InChI key

JDBJJCWRXSVHOQ-UTONKHPSSA-N

Gene Information

human ... MAOB(4129)

Application

Rasagiline mesylate has been used:
  • to test its neuroprotective effects in retinitis pigmentosa (RP) by apoptosis regulator, Bax/Bcl-2 modulation
  • as monoamine oxidase-B inhibitor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mouse model
  • as an anti-parkinsonian agent to test its rescue functionality in 6-hydroxydopamine-lesioned zebrafish larvae towards bradykinetic and dyskinetic-like behavior

Rasagiline mesylate may be used in MAO type B-mediated cell signaling studies.

Biochem/physiol Actions

Rasagiline mesylate is an effective therapeutic option in early stages of Parkinson′s disease. It improves the motor fluctuations in levodopa-treated patients and may be a useful adjunct to such patients. It has neuroprotective effects and increases the survival of dopaminergic neurons.
Rasagiline mesylate is an irreversible inhibitor of monoamine oxidase selective for MAO type B over type A by a factor of fourteen. It has anti-apoptotic and neuroprotectant activity and has been used as a treatment for Parkinson′s disease.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

J M Rabey et al.
Clinical neuropharmacology, 23(6), 324-330 (2001-09-29)
Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monotherapy in patients with early Parkinson's disease (PD) has already been reported. To evaluate the safety, tolerability
J P Finberg et al.
Neuroreport, 9(4), 703-707 (1998-04-29)
Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been primed with 10% serum for 12 h (p < 0.05). Rasagiline, but not deprenyl, also
Rita L Vaz et al.
Pharmacology, biochemistry, and behavior, 189, 172828-172828 (2019-12-01)
Parkinson's disease (PD) is known as a movement disorder due to characteristic motor features. Existing therapies for PD are only symptomatic, and their efficacy decreases as disease progresses. Zebrafish, a vertebrate in which parkinsonism has been modelled, offers unique features
Selegiline recovers synaptic plasticity in the medial prefrontal cortex and improves corresponding depression-like behavior in a mouse model of Parkinson's disease
Okano M, et al.
Frontiers in Behavioral Neuroscience, 13, 176-176 (2019)
Dhaval R Kalaria et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 127, 204-212 (2018-02-27)
Effective treatment of Parkinson's disease (PD) involves administration of therapeutic agents with complementary mechanisms of action in order to replenish, sustain or substitute endogenous dopamine. The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist)

Artículos

Our company offers many products related to histamine synthesis and metabolism for your research needs.

Our company offers many products related to histamine synthesis and metabolism for your research needs.

Our company offers many products related to histamine synthesis and metabolism for your research needs.

Our company offers many products related to histamine synthesis and metabolism for your research needs.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico